THAR

Tharimmune Inc

Add to Watchlist

Advanced Chart

1.234

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.234

Open

1.234

VWAP

1.23

Vol

200.00

Mkt Cap

5.72M

Low

1.234

Amount

246.80

EV/EBITDA(TTM)

Total Shares

786.03K

4.92M

EV/OCF(TTM)

P/S(TTM)

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.

Valuation Metrics

The current forward P/E ratio for Tharimmune Inc (THAR.O) is -0.17, compared to its 5-year average forward P/E of -0.77. For a more detailed relative valuation and DCF analysis to assess Tharimmune Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.77

Current PE

-0.17

Overvalued PE

0.19

Undervalued PE

-1.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00